Talis Expands Executive Team and Closes Additional Financing in Preparation for Commercial Launch of Talis One™ System

MENLO PARK, CALIF. – November 12, 2020 – Talis Biomedical Corporation, a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point of care, today announced it has strengthened its executive management team with the appointment of Rob Kelley as its first Chief Commercial Officer and Douglas Liu as Senior Vice President, Operations. Additionally, it has closed a new $126 million financing to support expansion of its operations and the commercial scale-up of the Talis One™ System and further expand the test menu. The Talis One System is a sample-to-answer, cloud-enabled, molecular diagnostic platform designed to provide rapid and highly accurate point-of-care tests for the detection of infectious diseases, including COVID-19. 

“The diversity of experience and proven leadership that Rob and Douglas bring to Talis will be invaluable as we gear up to potentially commercialize our COVID-19 molecular diagnostic assay for the Talis One platform in the United States,” said Brian Coe, Co-founder and Chief Executive Officer of Talis. “I’m proud of the strong leadership team and investor base we’re building to support our goal of empowering healthcare professionals to make patient care decisions at the point-of-care by providing them with fast, highly accurate and convenient diagnostic testing.”

Mr. Kelley brings to Talis more than two decades of sales and commercial leadership experience. In this newly created role, he will be responsible for commercial operations and will oversee the potential commercial launch of the Talis One System, initially for COVID-19 and subsequently for other infectious diseases. Prior to joining Talis, Mr. Kelley was Vice President of Sales and Commercial Development at Genalyte, where he was responsible for commercialization of the company’s diagnostic testing products, systems and services. Prior to that, he served as Vice President of Marketing at the diagnostics company Trovagene, where he oversaw marketing activities and was involved in business development and strategic planning. Mr. Kelley joined Trovagene from Illumina, where he was Director, Market Development, NEST (New, Emerging, Strategic and Transformative Markets), and prior to that was the Global Sales Manager for the Translational Genomics business unit where he launched the first clinically oriented, next-generation sequencing products and expanded the global sales team. Earlier in his career, he held positions in the sales organizations at Siemens Healthcare, Biosite and Merck, and was a Global Product Manager for Guidant. Mr. Kelley earned a B.S. in biology from Duke University and an M.B.A. from the UCLA Anderson School of Management. 

Mr. Liu brings to Talis in-depth experience in operations, strategic planning and R&D in molecular diagnostics. In this role, he will be responsible for global operations and manufacturing. Prior to joining Talis, Mr. Liu served as Senior Vice President of Global Operations at QIAGEN, where he was responsible for formulating and implementing the company’s strategy as a member of the Executive Committee. In that position, he oversaw manufacturing, quality assurance/quality control, supply chain, planning, purchasing, customer care, technical support, engineering, program management and facilities. He successfully integrated 15 companies into QIAGEN and supported the company’s growth while improving quality, customer satisfaction and compliance. Prior to QIAGEN, Mr. Liu had positions of increasing responsibility at Bayer Healthcare, Chiron and Abbott Labs. He also was Chair of BioHealth Innovation, a regional innovation intermediary focused on developing the life science industry in Maryland, as well as the co-chair of the Maryland Life Science Advisory Committee. Mr. Liu earned a B.S. from the University of Illinois and an M.B.A. with honors from Boston University. 

Talis intends to use the proceeds of the financing for commercial and operational scale-up, to support the launch of the Talis One System and COVID-19 test, and to continue development of additional tests for respiratory infections, infections impacting women’s health, and sexually transmitted infections. J.P. Morgan served as sole placement agent for the financing.

About the Talis One System

The Talis One System is a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform that, if authorized for marketing, could be rapidly deployed to distributed diagnostic settings in the United States and around the world to diagnose infectious diseases at the point-of-care. The Talis One assays are based on a proprietary, highly optimized nucleic acid isothermal amplification chemistry to achieve exceptional test performance much faster than traditional PCR. The system is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, elder care/assisted living facilities, and cancer treatment and dialysis centers.

COVID-19 is the first infectious disease that the Talis One System will support. Future infectious disease indications may include assays for other respiratory infections, such as influenza, as well as sexually transmitted infections (STIs) and other infections impacting women’s health. The Talis One instrument, currently in development, is designed to be managed remotely and to send test results to a cloud database for secure transmission, storage and review. Results are available in approximately 30 minutes. 

About Talis 

Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care. The company is developing the Talis One™ System, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis is headquartered in Menlo Park, California. For more information, please visit talis.bio.  

Talis Awarded NIH RADx Contract to Launch Talis One™ System for Point-of-Care COVID-19 Testing and Further Strengthens Financial Position and Leadership Team

Company awarded $25 million in NIH RADx contract and secures $100 million new financing 

Industry leaders appointed to executive team, Board of Directors and Scientific Advisory Board 

MENLO PARK, CALIF. – July 31, 2020 – Talis Biomedical Corporation, a company dedicated to developing high-performance point-of-care diagnostic tests for infectious diseases, today announced that it has secured a $25 million contract from the National Institutes of Health (NIH) for Phase 2 of its Rapid Acceleration of Diagnostics (RADx) initiative. Additionally, the company has completed an additional financing of $100 million. This new funding will be used to scale manufacturing for the launch of the Talis One™ diagnostic platform, which provides rapid and highly accurate detection of COVID-19 at the point-of-care. 

 The company also announced that industry veteran Roger Moody has joined the management team as Chief Financial Officer, Kim Popovits has joined the Board of Directors, and Walter Koch, Ph.D., has joined the Scientific Advisory Board. 

“This is an exciting milestone,” said Bruce Tromberg, Ph.D., Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and leader of RADx Tech, one of four components of the NIH RADx initiative. “It will help increase U.S. testing capacity exponentially. Game-changing technologies emerging from our RADx pipeline will inform public health measures to stop the spread of the virus and leave us better equipped to address future pathogens and other diseases.” 

“We are extremely proud that the NIH selected Talis, out of a field of 600 applicants, to be among the first teams to move to the final phase of the RADx initiative. This important funding will accelerate the commercialization of our Talis One System for the detection of COVID-19. Additionally, we are pleased to have the continued support of our investors, who share our excitement about the significant impact the Talis One System can deliver as a fast and reliable diagnostic testing platform for life-threatening and life-altering infectious diseases,” said Brian Coe, Co-Founder and Chief Executive Officer of Talis. 

“In response to the significant need for rapid, highly accurate testing solutions to help combat the pandemic, we were able to utilize our Talis One System, which we have been developing for clinical use in women’s health, to quickly develop an assay for SARS-CoV-2, the novel coronavirus that causes COVID-19. We are particularly focused on serving vulnerable populations, such as those in elder care facilities or patients with impaired immune systems. With the support of the NIH RADx program and proceeds from the new financing, we are confident that we will be able to accelerate our goal of making rapid diagnostic testing widely available,” added Coe.

The Talis One COVID-19 assay project is supported by the RADx program and has been funded in whole or in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92020C00010.

New Management Team, Board and SAB Members

Roger Moody, Talis’ new Chief Financial Officer, is an accomplished finance executive with a wealth of experience in finance operations. Before joining Talis, he was Chief Financial Officer at Clinical Genomics, a colorectal cancer diagnostics company. He also held Chief Executive and Chief Operating Officer roles at Glysure Limited, a UK-based company specializing in continuous glucose monitoring, and Chief Financial Officer and other executive positions at Nanosphere, Inc. and Medsn, Inc. He earned a B.S. in finance from Syracuse University and an M.B.A. with a focus in finance from the University of Chicago Booth School of Business.

Kim Popovits, a new member of Talis’ Board of Directors, is the former Chairman of the Board, President and Chief Executive Officer of Genomic Health. Under her leadership, Genomic Health became the world’s leading provider of genomic-based diagnostic tests that optimized the treatment of cancer, resulting in an acquisition by Exact Sciences in November 2019. Prior to joining Genomic Health, Ms. Popovits held several management roles at Genentech where she led the commercialization of 14 new therapies. In addition to Talis, she serves on the boards of 10X Genomics, Kiniksa Pharmaceuticals, Ltd. and MyoKardia, Inc. She earned a B.A. in business from Michigan State University.

“I was attracted to Talis because of the potential of the Talis One System to make a significant impact on the diagnosis and management of patients with serious infectious diseases, its world-class science and technology, and its experienced management team,” said Popovits. “By enabling fast, highly accurate and convenient molecular diagnostic results at the point-of-care, rather than days later from a central lab, Talis is well positioned to help people get the answers they need to make urgent, time-critical decisions during this pandemic and beyond.”

Dr. Walter Koch, a new member of Talis’ scientific advisory board, spent 22 years at Roche Molecular Systems, Inc., where he held a number of leadership positions of increasing responsibility. From 2005 to 2020, he served as Vice President and Head of Global Research, providing overall leadership and strategic direction for all research activities including technology development and evaluation, biomarker discovery and validation, infectious disease diagnostic assay early development, and oncology companion diagnostics. Prior to Roche, he spent 11 years at the U.S. Food and Drug Administration (FDA), where he held several positions, most recently Acting Lab Chief, Laboratory of Immunochemistry, in the Center for Biologics Evaluation and Research (CBER). He earned a B.S. in Chemistry from the University of Memphis and a Ph.D. in Pharmacology and Toxicology from the University of Tennessee Health Science Center. He completed a post-doctoral fellowship in Environmental Health Sciences at Johns Hopkins University.

About the Talis One System

The Talis One System is a compact, easy-to-use, highly accurate molecular diagnostic platform developed to enable rapid, point-of-care testing for infectious diseases. The Talis One assays are based on a proprietary, highly optimized nucleic acid isothermal amplification chemistry to achieve exceptional test performance much faster than traditional PCR. The system is designed for use in non-laboratory settings, such as physicians’ offices, urgent care clinics, elder care/assisted living facilities, cancer treatment and dialysis centers, and potentially the workplace. 

COVID-19 is the first infectious disease that the Talis One System will support. Future infectious disease indications may include assays for other respiratory infections, such as influenza, as well as sexually transmitted infections (STIs) and other infections impacting women’s health. The Talis One instrument can be managed remotely and sends test results to a cloud database for secure transmission, storage and review. Results are available in 30 minutes or less. 

About Talis 

Talis is dedicated to providing broad access to fast, highly accurate, actionable diagnostic testing to ensure better treatment and disease management for patients with infectious diseases. The company is developing the Talis One™ System, a compact, molecular diagnostic platform that is Cloud enabled, to provide rapid and reliable point-of-care testing for infectious diseases across a wide range of healthcare settings, from the doctor’s office to the hospital bedside to remote care settings. Talis is headquartered in Menlo Park, California. For more information, please visit talis.bio.

Talis Biomedical Corporation announces expansion of Scientific Advisory Board

Jane Schwebke, M.D., joins the Talis SAB

MENLO PARK, Calif., Oct. 11, 2018 /PRNewswire/ — Talis Biomedical Corporation is pleased to announce the expansion of their Scientific Advisory Board and the appointment of Dr. Jane Schwebke, MD, Professor of Medicine in the Infectious Disease Division at the University of Alabama at Birmingham and Consultant to the Jefferson County Department of Health STD clinic.

Talis is driven by the mission to transform medical care by enabling rapid molecular testing in the near patient setting.

Dr. Schwebke will work closely with the Talis team and with Dr. Rustem Ismagilov, chair of the SAB, to advance the mission in the areas of sexually transmitted infections and Women’s Health.

Brian Coe, Talis’ Chief Executive Officer, stated: “We are honored to announce the expansion of our Scientific Advisory Board. It is a testament of the scientific and clinical enthusiasm for our pioneering solution, and we are privileged to welcome Dr. Jane Schwebke to our SAB.”

Dr. Schwebke stated, “I am very excited to serve on the Talis SAB. There is a critical need for rapid STD and women’s health diagnostic testing and I believe Talis will provide the solution.”

About Dr. Schwebke:

Dr. Schwebke received her medical degree from Northwestern University Feinberg School of Medicine and has been in practice for more than 20 years. She began her career in the field of STDs in 1987 during her fellowship in Infectious Disease at the University of Washington in Seattle. After her fellowship she became the medical director of the Harborview STD Clinic in Seattle where she remained until April 1991. She subsequently had a joint appointment at Northwestern University in Chicago and the Chicago Department of Health where she became the Director for the City of Chicago’s STD/HIV Program. Important contributions to the Program included merging STD and HIV, initiating HIV clinical care in the city’s clinics, initiation of cervical cancer screening in the STD clinics, creation of a clinical and behavioral research program, development of an adolescent clinic combining STD, HIV, and contraception services for Hispanic youth and addition of TB skin testing for STD clinic patients. She has been a faculty member at the University of Alabama at Birmingham for the past 24 years. Her major areas of research include the pathogenesis of bacterial vaginosis and its relationship to the acquisition of STDs as well as epidemiology and control of trichomoniasis.